Cargando…
Romidepsin in the treatment of cutaneous T-cell lymphoma
The most common subtypes of primary cutaneous T-cell lymphoma (CTCL) are mycosis fungoides and Sézary syndrome. Clinical manifestations and prognosis in CTCL are highly variable. Improving the management of this incurable disease with limited toxicity is an active area of research. Romidepsin is a n...
Autores principales: | Jain, Salvia, Zain, Jasmine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262342/ https://www.ncbi.nlm.nih.gov/pubmed/22287862 http://dx.doi.org/10.2147/JBM.S9649 |
Ejemplares similares
-
Novel therapeutic agents for cutaneous T-Cell lymphoma
por: Jain, Salvia, et al.
Publicado: (2012) -
Romidepsin for the Treatment of Peripheral T-Cell Lymphoma
por: Barbarotta, Lisa, et al.
Publicado: (2015) -
Complete response to romidepsin as monotherapy in treatment-resistant subcutaneous panniculitis-like T-cell lymphoma
por: Jothishankar, Balaji, et al.
Publicado: (2020) -
Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma
por: Poligone, Brian, et al.
Publicado: (2011) -
Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma
por: Kalac, Matko, et al.
Publicado: (2023)